clinical study of regulatory t cells (tregs) in the treatment of neurodegenerative diseases

Conditions: Amyotrophic Lateral Sclerosis (ALS); Alzheimer's Disease(AD); Multiple System Atrophy, MSA

Summary: an open, multi- center phase ⅰ clinical study evaluating the safety and efficacy of autologous human polyclonal regulatory t cell injection (np001 cell injection) in patients with neurodegenerative diseases (als, msa, ad).

this is an open-label, non-randomized, multi-center clinical trial of single-agent np001 cell injection in patients with with neurodegenerative diseases (als, msa, ad). after subject consents to the study, an apheresis procedure will be performed to collect cells to manufacture the investigational product, np001 cell injection. np001 cell injection are manufactured ex vivo to yield enriched tregs. this study is evaluating np001 cell injection at the dose of 1x e6 cells, 1x e7 cells, and 1x e8 cells/times, with up to 3 times separated by 4 weeks among dosing (intrathecally on days 1, 29, and 57). study subjects are then followed for several months to capture safety and efficacy parameters. the total duration of np001 cell injection and follow-up interval on this protocol is approximately 12-months.

Eligibility criteria:
inclusion criteria: - patients must meet all of the following criteria to be eligible for enrollment in this study: 1. male or female patients aged 18 to 70 years; 2. according to current international diagnostic criteria: ①als: defined by the gold coast diagnostic criteria (shefner, 2020) as having a diagnosis of sporadic or familial amyotrophic lateral sclerosis (als), diagnosed as a probable, probable, or definite patient with laboratory support according to the world federation of neurology el escorial criteria; ②msa: umsars i (question 11 omitted) score of 5 -17 and able to walk independently (i.e., able to walk for at least 40 meters without the use of crutches or walkers and without other support (e.g., holding the arm or touching)). expected survival of at least 3 years in the opinion of the investigator. normal cognition as assessed by the montreal cognitive assessment (moca), i.e., ≥26. ③ad: age 65 or above; clinical diagnosis of ad (moca 10-20 and clinical dementia rating scale/cdr = 1) on stable doses of medication for at least three months, no clinically significant findings on blood tests, able to voluntarily provide written informed consent. 3. if there is a stable dose for more than one month prior to study entry. for example, patients with als can continue treatment with riluzole (rilutek®) and/or edaravone (radicava®); 4. patients must have \> two weeks after the end of major surgery and after the completion of participation in other research trials; 5. patients must have recovered from clinical toxicity (ctcae \[5th edition\] toxicity values have resolved to \< 2); 6. serum creatinine less than or equal to 2.0 mg/dl; 7. aspartate aminotransferase (ast) and alanine aminotransferase (alt) \< 3 x upper limit of normal; 8. bilirubin \< 1.5 (except gilbert's disease); 9. lung slow vital capacity (svc) \> 70% of predicted normal; 10. no history of abnormal bleeding tendency; 11. informed consent must be obtained prior to performing any study-related procedures that are not part of standard medical care, with the understanding that the participant may withdraw from the study without influence for the future medical care. exclusion criteria: - subjects with any of the following cannot be enrolled in this study: 1. uncontrolled infection; 2. \< 3 drugs do not adequately control hypertension; 3. documented history of pulmonary embolism within 6 months of enrollment; 4. clinically significant cardiology, defined as: myocardial infarction, nyha-graded class iii or iv heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmia, or ecg evidence of acute ischemia or abnormal conduction system within 6 months prior to enrollment; 5. patients with a history of coronary artery bypass grafting or angioplasty will be evaluated by cardiology and considered on a case-by-case basis; 6. seropositive for hiv, hepatitis b or hepatitis c; 7. pregnant or lactating patients; 8. patients of childbearing potential or males with partners of childbearing potential who are unwilling to use contraception; 9. participation in any other interventional study; 10. treatment with another investigational drug, biologic, or device within 30 days or 5 half-lives (whichever is longer) of the screening period. patient participation in observational/non-interventional clinical studies will be discussed with the medical monitor; 11. prior treatment with als, msa or ad gene or cell therapy; 12. history of clinically significant tumor, liver or kidney disease, or other uncontrolled disease; 13. presence of a feeding tube; 14. current use of antipsychotics, antiepileptic drugs (except benzodiazepines, gabapentin, pre-bahrain) or class 1 (e.g., flecainide) or class 3 (e.g., amiodarone) antiarrhythmic drugs; 15. subjects who, in the opinion of the investigator, are at significant risk of suicide; 16. other conditions that the investigator considers unsuitable for enrollment.

Keywords: treg regulatory t cells neurodegenerative diseases alzheimer's disease multiple system atrophy amyotrophic lateral sclerosis